SCHEMBL24696043

SCHEMBL24696043

CCOC(=O)c1cc2nc(CC3CCC4CCCCC4C3)cc(Cl)n2n1

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALOX5 P09917 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ FAAH O00519 5/20 0.34
▸ KMT2A Q03164 2/20 0.33
▸ MGLL Q99685 1/20 0.33
▸ NPC1 O15118 2/20 0.32
▸ RAB9A P51151 2/20 0.32
▸ CSNK1D P48730 1/20 0.32
▸ RXFP1 Q9HBX9 1/20 0.32
▸ ADORA3 P0DMS8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24696046 0.90 ALOX5 (0.39) ALOX5KDM4EALDH1A1POLBHPGD
SCHEMBL24696340 0.89 KDM4E (0.39) KDM4EALDH1A1POLBHPGDSMN1; SMN2
SCHEMBL24695625 0.88 SMN1; SMN2 (0.40) KDM4EALDH1A1POLBHPGDSMN1; SMN2
SCHEMBL24695971 0.88 SMN1; SMN2 (0.40) KDM4EALDH1A1POLBHPGDSMN1; SMN2
SCHEMBL24695641 0.87 KDM4E (0.39) KDM4EALDH1A1POLBHPGDSMN1; SMN2
SCHEMBL24696044 0.87 ALOX5 (0.35) ALOX5KDM4EALDH1A1POLBHPGD
SCHEMBL24696049 0.86 ALOX5 (0.34) ALOX5KDM4EALDH1A1POLBHPGD
SCHEMBL24696138 0.86 KDM4E (0.39) KDM4EALDH1A1POLBHPGDSMN1; SMN2
SCHEMBL24695978 0.85 HPGD (0.38) KDM4EALDH1A1POLBHPGDSMN1; SMN2
SCHEMBL24696245 0.84 KDM4E (0.39) KDM4EALDH1A1POLBHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022255408-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-12-08 — — WO disclosed
Send feedback